CIK 0001604464 · Non-accelerated filer<br>Smaller reporting company
Atara Biotherapeutics, Inc.
Sign in to watch- Ticker
- ATRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460920988
- Phone
- 805-623-4211
- Business address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- DEF 14A Proxy Proxy Statement
- 8-K Event Executive or director change
- UPLOAD Other SEC-generated Letter
- PRE 14A Proxy Proxy Statement (Preliminary)
- 8-K Event Regulation FD disclosure
- 4 Open-market sale President and CEO sold 15,679 shares at $3.63 ($56,868)
- 4 Open-market sale SVP, GC & Secretary sold 4,221 shares at $3.63 ($15,310)
- 4 Open-market sale Chief Financial Officer sold 6,871 shares at $3.63 ($24,921)
- 4 Open-market sale EVP, Head of R&D sold 5,074 shares at $3.63 ($18,403)
- 4 Grant or award President and CEO acquired 324,711 shares (grant or award)
- 4 Grant or award EVP, Chief Technical Officer acquired 139,700 shares (grant or award)
- 4 Grant or award EVP, Head of R&D acquired 141,328 shares (grant or award)
- 4 Grant or award SVP, GC & Secretary acquired 155,375 shares (grant or award)
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- EFFECT Other Notice of Effectiveness
- 4 Open-market sale Chief Financial Officer sold 2,485 shares at $5.46 ($13,568)
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
Page 15 of 57 · 1,133 filings